Home Cart Sign in  
Chemical Structure| 123171-59-5 Chemical Structure| 123171-59-5

Structure of Cefepime 2HCl Monohydrate
CAS No.: 123171-59-5

Chemical Structure| 123171-59-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cefepime 2HCl H2O is a fourth-generation cephalosporin antibiotic with an extended spectrum of activity against Gram-positive and Gram-negative bacteria and greater activity against both types of organism than third-generation agents.

Synonyms: Cefepime (hydrochloride hydrate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cefepime 2HCl Monohydrate

CAS No. :123171-59-5
Formula : C19H28Cl2N6O6S2
M.W : 571.50
SMILES Code : C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C(O)=O)N2C3=O)CCCC1.[H]O[H].[H]Cl.[Cl-]
Synonyms :
Cefepime (hydrochloride hydrate)
MDL No. :MFCD12545909

Safety of Cefepime 2HCl Monohydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Staphylococcus aureus JKD6159 64 µg/mL 24 h Evaluate the combination effect against community-associated MRSA strain JKD6159, showing synergistic bactericidal activity. BMC Microbiol. 2024 Oct 29;24(1):442
Staphylococcus aureus ATCC™700699 256 µg/mL 24 h Assess the combination effect against ATCC™700699, demonstrating additive activity. BMC Microbiol. 2024 Oct 29;24(1):442
Staphylococcus aureus ATCC™43300 128 µg/mL 24 h Assess the combined antibacterial effect against MRSA strain ATCC™43300, demonstrating synergistic bactericidal activity. BMC Microbiol. 2024 Oct 29;24(1):442
Staphylococcus aureus ATCC™29213 4 µg/mL 24 h Evaluate the antibacterial synergy of Leu10-teixobactin and cefepime combination, showing synergistic bactericidal activity against ATCC™29213. BMC Microbiol. 2024 Oct 29;24(1):442
Pseudomonas aeruginosa 0.06 to 256 mg/L 18 to 20 h To evaluate the activity of cefepime alone and in combination with taniborbactam against ESBL-producing isolates. Results showed that the median MIC of cefepime alone was 32 mg/L, MIC90 was 128 mg/L, with 86% resistant isolates. With taniborbactam, the median MIC decreased to 8 mg/L, MIC90 to 16 mg/L, and 36% of isolates remained resistant. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02338-20
Klebsiella pneumoniae 0.06 to 256 mg/L 18 to 20 h To evaluate the activity of cefepime alone and in combination with taniborbactam against ESBL-producing isolates. Results showed that the median MIC of cefepime alone was 32 mg/L, MIC90 was 256 mg/L, with 72% resistant isolates. With taniborbactam, the median MIC decreased to 0.25 mg/L, MIC90 to 1 mg/L, and no resistant isolates were found. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02338-20
Escherichia coli 0.06 to 256 mg/L 18 to 20 h To evaluate the activity of cefepime alone and in combination with taniborbactam against ESBL-producing isolates. Results showed that the median MIC of cefepime alone was 32 mg/L, MIC90 was 256 mg/L, with 72% resistant isolates. With taniborbactam, the median MIC decreased to 0.125 mg/L, MIC90 to 1 mg/L, and no resistant isolates were found. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02338-20
Carbapenemase-producing Enterobacterales 0.5-128 mg/L To evaluate the in vitro activity of cefepime in combination with novel β-lactamase inhibitors (zidebactam, taniborbactam, and enmetazobactam). Results showed that cefepime/zidebactam and cefepime/taniborbactam combinations exhibited the highest activity against most strains. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167621

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Neutropenic murine thigh infection model Intravenous injection 25-200 mg/kg Every 4 hours for 26 hours To evaluate the in vivo efficacy of cefepime-enmetazobactam against ESBL-producing K. pneumoniae, results showed that enmetazobactam restored the efficacy of cefepime against all tested isolates and identified the PK-PD target for enmetazobactam as 44% fT>2 μg/ml. Antimicrob Agents Chemother. 2020 May 21;64(6):e00078-20
ICR mice Normal and corneal kindled mice Intravenous injection 250 mg/kg and 500 mg/kg Single injection To compare the convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Results showed that cefepime at 500 mg/kg significantly increased the mean seizure stage and produced EEG spikes. Antimicrob Agents Chemother. 2014 Aug;58(8):4380-3

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.75mL

1.75mL

0.87mL

17.50mL

3.50mL

1.75mL

References

 

Historical Records

Categories